We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+10.91%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$254M
AUM Growth
+$22.2M
Cap. Flow
+$5.01M
Cap. Flow %
1.97%
Top 10 Hldgs %
45.13%
Holding
116
New
12
Increased
26
Reduced
50
Closed
24

Top Buys

Rank Stock Value
1
LENZ
LENZ Therapeutics
LENZ
+$20.9M
2
BOLD
Boundless Bio
BOLD
+$12.2M
3
ZBH icon
Zimmer Biomet
ZBH
+$3.72M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.08M
5
PGNY icon
Progyny
PGNY
+$2.87M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$3.69M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$3.59M
3
ANNX icon
Annexon
ANNX
+$2.96M
4
FDMT icon
4D Molecular Therapeutics
FDMT
+$2.89M
5
VERA icon
Vera Therapeutics
VERA
+$2.82M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
51
Moderna
MRNA
$22.5B
$1.57M 0.62%
14,740
-1,360
-8% -$137K
BIIB icon
52
Biogen
BIIB
$29.8B
$1.5M 0.59%
6,967
-8,860
-56% -$2.08M
EW icon
53
Edwards Lifesciences
EW
$50.9B
$1.5M 0.59%
15,650
-6,250
-29% -$525K
EFTR
54
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$1.37M 0.54%
95,305
-1
-0% -$12
TSBX
55
DELISTED
Turnstone Biologics
TSBX
$1.36M 0.53%
517,648
– –
SMMT icon
56
Summit Therapeutics
SMMT
$10.5B
$1.3M 0.51%
315,000
+285,000
+950% +$1.13M
ALT icon
57
Altimmune
ALT
$574M
$939K 0.37%
92,240
-78,560
-46% -$799K
VSTM icon
58
Verastem
VSTM
$505M
$876K 0.34%
74,200
-129,127
-64% -$1.49M
ILMN icon
59
Illumina
ILMN
$30.5B
$862K 0.34%
6,456
-329
-5% -$44.1K
SNY icon
60
Sanofi
SNY
$103B
$616K 0.24%
12,670
-1,420
-10% -$69.3K
ASND icon
61
Ascendis Pharma A/S
ASND
$16B
$606K 0.24%
4,011
-430
-10% -$61.4K
UTHR icon
62
United Therapeutics
UTHR
$25.7B
$596K 0.23%
2,595
-220
-8% -$49.6K
RPRX icon
63
Royalty Pharma
RPRX
$25.4B
$590K 0.23%
19,420
-1,150
-6% -$33.9K
PCVX icon
64
Vaxcyte
PCVX
$7.81B
$581K 0.23%
8,500
+450
+6% +$31.2K
NBIX icon
65
Neurocrine Biosciences
NBIX
$16.9B
$579K 0.23%
4,195
-250
-6% -$34.1K
ONC
66
BeOne Medicines Ltd
ONC
$32.2B
$577K 0.23%
3,692
-60
-2% -$9.66K
APLS
67
DELISTED
Apellis Pharmaceuticals
APLS
$568K 0.22%
9,670
+4,450
+85% +$284K
INCY icon
68
Incyte
INCY
$24.1B
$536K 0.21%
9,405
-700
-7% -$42K
MEDP icon
69
Medpace
MEDP
$16.1B
$522K 0.21%
1,291
-80
-6% -$28.1K
ROIV icon
70
Roivant Sciences
ROIV
$24B
$521K 0.2%
49,457
+13,000
+36% +$140K
BBIO icon
71
BridgeBio Pharma
BBIO
$15.7B
$498K 0.2%
16,105
+3,150
+24% +$107K
ITCI
72
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$490K 0.19%
7,080
-340
-5% -$23.4K
JAZZ icon
73
Jazz Pharmaceuticals
JAZZ
$15.8B
$469K 0.18%
3,894
-200
-5% -$24.5K
INSM icon
74
Insmed
INSM
$21B
$446K 0.18%
16,421
+2,610
+19% +$73K
IONS icon
75
Ionis Pharmaceuticals
IONS
$8.86B
$438K 0.17%
10,100
+3,620
+56% +$173K
1 2
3
4 5

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q1 2024 Portfolio in Review

As of Q1 2024, Sectoral Asset Management held 116 positions worth $254M, up 9.5% from $232M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sectoral Asset Management's Q1 2024 filing shows 12 new, 26 increased, 50 reduced and 24 closed positions. Its largest new stake was Boundless Bio: 855,875 shares worth $12.2M. The largest sale was Amgen, an estimated $3.69M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • Sectoral Asset Management's largest Q1 2024 buy was Boundless Bio: 855,875 shares worth $12.2M.
  • Sectoral Asset Management added most to LENZ Therapeutics in Q1 2024, an estimated $20.9M increase.
  • Sectoral Asset Management's biggest Q1 2024 reduction was Amgen, cutting an estimated $3.69M.
  • Sectoral Asset Management fully exited Edgewise Therapeutics in Q1 2024, selling an estimated $3.59M.
  • Sectoral Asset Management's ten largest holdings make up 45% of its $254M portfolio in Q1 2024.
  • Sectoral Asset Management opened 12 new positions and closed 24 in Q1 2024.
  • Sectoral Asset Management's portfolio value rose 9.5% quarter-over-quarter to $254M.

Based on Sectoral Asset Management's 13F filing for Q1 2024, filed 14 May 2024.